Research and development of next generation of antibody-based therapeutics

Acta Pharmacologica Sinica

Volumn 31, Issue 9, 2010, Pages 1198-1207

  Li, Jing ^a   Zhu, Zhenping ^a,b  

^a Protein Sciences and Design   (United States)

^b Kadmon Pharmaceuticals   (United States)

Author keywords

antibody design; antibody efficacy enhancement; antibody engineering; antibody therapeutics; next generation of antibody; novel antibody format

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANKYRIN; ANTIBODY CONJUGATE; ARZERRA; AVE 9633; BASILIXIMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; C 326; CANAKINUMAB; CD16 ANTIGEN; CDX 011; CERTOLIZUMAB PEGOL; CETUXIMAB; COTARA; CT 322; DACLIZUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMGN 242; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; INOTUZUMAB OZOGAMICIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MDX 1203; MEDI 547; MP 0112; NATALIZUMAB; NIMOTUZUMAB; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; PANITUMUMAB; PROLIA; RANIBIZUMAB; REMOVAB; RITUXIMAB; SGN 33; SIMPONI; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB DM1; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VASCULOTROPIN INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; BREAST CANCER; COLORECTAL CANCER; CROHN DISEASE; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SPECIFICITY; DRUG UPTAKE; GENOTYPE; GLIOBLASTOMA; GLYCOSYLATION; LYMPHOCYTE ACTIVATION; MACROPHAGE; MONOTHERAPY; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PROTEIN DNA INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG APPROVAL; DRUG DESIGN; HUMANS; PROTEIN ENGINEERING;

EID: 77956381860     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.120     Document Type: Review

References (105)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
2. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-6855
3. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-525
4. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029-10033
5. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352: 624-628
6. Taylor LD, Carmack CE, Schramm SR, Mashayekh R, Higgins KM, Kuo CC, et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res 1992; 20: 6287-6295
7. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368: 856-859
8. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7: 13-21.
9. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10.
10. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007; 13: 276-281
11. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113: 2714-2723
12. Marvin JS, Zhu Z. Bispecific antibodies for dual-modality cancer therapy: Killing two signaling cascades with one stone. Curr Opin Drug Discov Devel 2006; 9: 184-193
13. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, et al. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res 1990; 50: 4227-4232
14. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944
15. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 2001; 61: 7002-7008
16. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279: 2856-2865
17. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant igg-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280: 19665-19672
18. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99: 1415-1425
19. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, et al. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 2009; 11: 594-604.
20. Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, et al. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230: 159-171
21. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001; 248: 47-66.
22. Carter P, Ridgway J, Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J Hematother 1995; 4: 463-470
23. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248: 7-15.
24. Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26: 649-658
25. Kipriyanov SM, Le GF. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 2004; 7: 233-242
26. Alt M, Muller R, Kontermann RE. Novel tetravalent and bispecific IgGlike antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999; 454: 90-94
27. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008; 34: 49-60.
28. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 2004; 30: 165-172
29. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-357
30. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-dm1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290
31. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-169
32. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009; 9: 982-1004.
33. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758
34. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with her-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796
35. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between fc{gamma}RIIIa-v158f and fc{gamma}riia-h131r polymorphisms in white patients, and for an fc{gamma}riiia-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26: 5489-5491
36. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591-6604
37. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-4010
38. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineers perspective. Drug Discov Today 2007; 12: 898-910.
39. Allan B. Variant Fc regions. ed. Applied Molecular Evolution. PCT/US2006/025276. 2010. Ref Type: Patent
40. Hansen G, et al. Altered antibody Fc regions and uses thereof. ed. Diversa/Medarex. PCT/US2006/011048. 2010. Ref Type: Patent.
41. Siberil S, Dutertre CA, Boix C, Bonnin E, Mnez R, Stura E, et al. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 2006; 106: 111-118
42. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an fc-engineered anti-cd19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057
43. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 3863-3872
44. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87: 614-622
45. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat Biotech 1999; 17: 176-180
46. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24: 1591-1597
47. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24: 210-215
48. Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, et al. Compensation of endogenous IgG mediated inhibition of antibodydependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol Immunol 2007; 44: 1815-1817
49. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673
50. DallAcqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281: 23514-23524
51. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dallacqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46: 1750-1755
52. Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70: 3269-3277
53. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28: 157-159
54. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176: 346-356
55. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279: 6213-6216
56. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. J Biol Chem 2007; 282: 1709-1717
57. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136
58. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, et al. Single-chain antigen-binding proteins. Science 1988; 242: 423-426
59. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-6448
60. Quiocho FA. Protein engineering. Making of the minibody. Nature 1993; 362: 293-294
61. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-448
62. Dooley H, Flajnik MF, Porter AJ. Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 2003; 40: 25-33.
63. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21: 484-490
64. Blick SK, Curran MP. Certolizumab Pegol: In Crohns Disease. BioDrugs 2007; 21: 195-201 .
65. Muller,D. Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282: 12650-12660
66. Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006; 19: 291-297
67. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008; 21: 283-288
68. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods 2006; 3: 887-889
69. Skerra A. Imitating the humoral immune response. Curr Opin Chem Biol 2003; 7: 683-693
70. Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 2006; 13: 549-556
71. Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23: 1556-1561
72. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plnckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003; 332: 489-503.
73. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007; 369: 1015-1028 .
74. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004; 22: 575-582
75. Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275: 2668-2676
76. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". Drug Discov Today 2005; 10: 23-33.
77. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R, et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996; 380: 548-550
78. Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23: 1257-1268
79. Chen JD, Yang Q, Yang AG, Marasco WA, Chen SY. Intra-and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther 1996; 7: 1515-1525
80. Tanaka T, Lobato MN, Rabbitts TH. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigenspecific Intrabodies. J Mol Biol 2003; 331: 1109-1120
81. Jendreyko N, Popkov M, Rader C, Barbas CF. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 8293-8298 .
82. Cohen PA. Intrabodies. Targeting scFv expression to eukaryotic intracellular compartments. Methods Mol Biol 2002; 178: 367-378
83. Boldicke T, Weber H, Mueller PP, Barleon B, Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J Immunol Methods 2005; 300: 146-159
84. Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996; 13: 275-282
85. Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL, et al. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 2005; 65: 2815-2824
86. Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z, et al. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 2005; 4: 1801-1809
87. Strube RW, Chen SY. Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-Fc intrabodies. J Immunol Methods 2002; 263: 149-167
88. Williams BR, Zhu Z. Intrabody-based approaches to cancer therapy: status and prospects. Curr Med Chem 2006; 13: 1473-1480
89. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, et al. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing Murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Human Gene Ther 1999; 10: 1453-1467
90. Steinberger P, Andris-Widhopf J, Bühler B, Torbett BE, Barbas CF. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 2000; 97: 805-810
91. Doorbar J, Griffin H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther 2007; 7: 677-689
92. Messer A, Lynch SM, Butler DC. Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opin Biol Ther 2009; 9: 1189-1197
93. Mhashilkar AM, Doebis C, Seifert M, Busch A, Zani C, Soo Hoo J, et al. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther 2002; 9: 307-319
94. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000; 6: 3081-3087
95. Nakata Y, Kim TK, Shetzline S, Gewirtz AM. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer. Crit Rev Eukaryot Gene Expr 2005; 15: 163-182
96. Persengiev SP, Zhu X, Green MR. Nonspecific, concentrationdependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004; 10: 12-18
97. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419
98. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta Mol Cell Res 2002; 1591: 109-118
99. Sapra P, Moase EH, Ma J, Allen TM. Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab fragments. Clin Cancer Res 2004; 10: 1100-1111
100. Elliott G, OHare P. Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 1997; 88: 223-233
101. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193
102. Tse E, Lobato MN, Forster A, Tanaka T, Chung GT, Rabbitts TH. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol 2002; 317; 85-94.
103. Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, et al. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-[kappa]B transactivation. J Mol Biol 2004; 335: 193-207.
104. der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, et al. Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem 2002; 277: 45075-45085
105. Worlds top-selling drugs in 2014 vs 2010. 2010. Reuters News. 4-13-2010. Ref Type: Report